Darwin Wealth Management LLC Boosts Holdings in Dyne Therapeutics, Inc. $DYN

Darwin Wealth Management LLC lifted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 34.4% in the first quarter, HoldingsChannel reports. The firm owned 154,862 shares of the company’s stock after buying an additional 39,595 shares during the quarter. Darwin Wealth Management LLC’s holdings in Dyne Therapeutics were worth $2,808,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its holdings in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics during the second quarter worth $30,378,000. Perceptive Advisors LLC increased its position in shares of Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after acquiring an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after acquiring an additional 2,565,570 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Down 3.5%

DYN opened at $23.42 on Friday. Dyne Therapeutics, Inc. has a one year low of $8.24 and a one year high of $25.00. The company has a market cap of $3.87 billion, a P/E ratio of -7.27 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The business’s 50-day simple moving average is $19.24 and its 200-day simple moving average is $18.35.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the firm posted ($1.05) EPS. As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insider Activity

In related news, Director Jason P. Rhodes sold 480,240 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $22.79, for a total value of $10,944,669.60. Following the transaction, the director directly owned 875,912 shares of the company’s stock, valued at $19,962,034.48. This trade represents a 35.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 3,111,730 shares valued at $64,079,704. Insiders own 9.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DYN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. TD Cowen assumed coverage on Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating for the company. Sanford C. Bernstein upped their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.